XML 83 R64.htm IDEA: XBRL DOCUMENT
v3.20.4

Commitments and Contingencies - CFTR Activators and Inhibitors - Additional Information (Detail) - USD ($) $ in Thousands | 1 Months Ended | 12 Months Ended | 46 Months Ended |
--- | --- | --- | --- | ---
Mar. 31, 2019 | Dec. 31, 2020 | Dec. 31, 2020 | Dec. 31, 2019
CFTR activators and inhibitors |  |  |  |
Milestone obligations under license agreements |  | $ 350 | $ 350 | $ 0
CFTR Activators and Inhibitors |  |  |  |
CFTR activators and inhibitors |  |  |  |
Tiered royalties payable on future net sales |  | single-digit |  |
Development and milestone payments to third party |  |  | 1,200 |
Regulatory Approval Milestone | CFTR Activators and Inhibitors |  |  |  |
CFTR activators and inhibitors |  |  |  |
Possible future milestone payments |  | $ 12,200 |  |
Future Regulatory Approval And Sales Milestones | CFTR Activators and Inhibitors |  |  |  |
CFTR activators and inhibitors |  |  |  |
Possible future milestone payments |  | 33,000 |  |
Development And Milestone Payment, Conclusion Of Phase I Study | CFTR Activators and Inhibitors |  |  |  |
CFTR activators and inhibitors |  |  |  |
Development and milestone payments to third party | $ 200 |  |  |
Possible future milestone payments |  | 350 |  |
Milestone obligations under license agreements |  | 350 | $ 350 |
Maximum | Development And Milestone Payment, Conclusion Of Phase I Study | CFTR Activators and Inhibitors |  |  |  |
CFTR activators and inhibitors |  |  |  |
Possible future milestone payments |  | $ 1,100 |  |

X
- Definition Accrued Milestone Obligations Under License Agreements + References No definition available. + Details
Name: | vnda_AccruedMilestoneObligationsUnderLicenseAgreements
Namespace Prefix: | vnda_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition CFTR activators and inhibitors [Abstract] + References No definition available. + Details
Name: | vnda_CftrActivatorsAndInhibitorsAbstract
Namespace Prefix: | vnda_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Development And Milestone Obligations Paid To Third Party + References No definition available. + Details
Name: | vnda_DevelopmentAndMilestoneObligationsPaidToThirdParty
Namespace Prefix: | vnda_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Total amount potentially due to third party under license agreement based on achievement of pre-new drug application approval milestones. + References No definition available. + Details
Name: | vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty
Namespace Prefix: | vnda_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Tiered royalties potentially due to third party under license agreement based on future net sales. + References No definition available. + Details
Name: | vnda_TieredRoyaltiesPayableOnFutureNetSales
Namespace Prefix: | vnda_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=vnda_CftrActivatorsAndInhibitorsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vnda_RegulatoryApprovalMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vnda_FutureRegulatoryApprovalAndSalesMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vnda_DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |